N1087 (oral minoxidil)
N1087 (oral minoxidil) is in Phase 3 for female pattern hair loss, developed by Eurofarma Laboratórios.
Eurofarma's oral minoxidil solution, registered for Phase 3s in women and in men that are planned to start in 2027.
- Developed by
- Eurofarma Laboratórios
- Current phase
- Phase 3
- Mechanism
- Potassium channel opener
- Indications
- Female pattern hair loss
- Also known as
- N1087, N-1087
- Last public activity
- January 2026
- Copy last reviewed
- September 2026
- Record confidence
- Medium
Large confirmatory trials. The last step before filing.
Opens potassium channels in the follicle - minoxidil's mechanism, thought to improve blood flow and prolong the growth phase.
A research record, not medical advice: being listed here says nothing about whether a treatment works or whether it is right for you. Talk to a dermatologist about your own case.
Why it matters
The registry names it: the men's study is titled as oral minoxidil, and both trials describe an oral solution given in drops and titrated from 0.5 to 2 mg a day, the range dermatologists already use off-label. Female pattern hair loss is chronically under-served by the pipeline, so a registrational trial aimed at it is worth recording before it starts: 372 women against placebo, estimated to begin in January 2027, with a matching 372-man study the same month and no sites listed for either. If they run, they would join the Spanish and American programmes trying to give oral minoxidil a label, as the low-dose oral minoxidil entry records.
Development history
No phase changes recorded yet.
Registered trials
Pulled automatically from ClinicalTrials.gov. Matching is by name and development code, so occasional gaps are possible — tell us if you spot one.
Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of N1087 in Participants With Female Pattern Hair Loss (MINORA-WOMEN)
Eurofarma Laboratorios S.A. · n=372 · January 2027
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first.
Sources
- N1087 in female pattern hair loss — ClinicalTrials.gov
- Phase 3 Study to Evaluate the Efficacy and Safety of Oral Minoxidil (N1087) in Men With Androgenetic Alopecia — ClinicalTrials.gov
Related programmes
Other programmes in the register with the same mechanism: Potassium channel opener.
Cite this page
Hair Pipeline, "N1087 (oral minoxidil) — development record", hairpipeline.com/pipeline/n1087